Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTP7EGM)

• DTT Name: Dual specificity protein kinase TTK (MPS1) DTT Info
• Gene Name: TTK

Molecule-Related Drug & Molecule List

3 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BAY1161909	DMUK6YM	Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]
BOS172722	DMU790L	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
CFI-402257	DMH701Q	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]

3 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tricyclic isoxazoloquinazoline derivative 2	DMH4TY1	N. A.	N. A.	Patented	[4]
Tricyclic isoxazoloquinazoline derivative 3	DML2PWF	N. A.	N. A.	Patented	[4]
Tricyclic isoxazoloquinazoline derivative 4	DM8VIM4	N. A.	N. A.	Patented	[4]

2 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One	DMDN12L	Discovery agent	N.A.	Investigative	[5]
GNE-7915	DMYWM56	Discovery agent	N.A.	Investigative	[6]

References

• [1] National Cancer Institute Drug Dictionary (drug id 761238).
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3127-3132.
• [4] Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
• [5] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [6] Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem. 2014 Feb 13;57(3):921-36.